
|Videos|November 6, 2017
Dr. Luke Discusses the Combination of PD-1 and IDO Inhibitors in Melanoma
Author(s)Jason Luke, MD
Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br />
Advertisement
Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5






























